PMID- 10399963
OWN - NLM
STAT- MEDLINE
DCOM- 19990727
LR  - 20190708
IS  - 0020-7136 (Print)
IS  - 0020-7136 (Linking)
VI  - 82
IP  - 3
DP  - 1999 Jul 30
TI  - Interleukin-2-induced, melanoma-specific T cells recognize CAMEL, an unexpected
      translation product of LAGE-1.
PG  - 442-8
AB  - Melanoma-specific cytotoxic T lymphocytes (CTLs) were induced by in vitro
      stimulation of peripheral blood mononuclear cells of a melanoma patient with
      autologous IL-2-producing melanoma 518/IL2.14 cells. CTL clone 1/29 recognized,
      in addition to autologous melanoma cell lines, a panel of HLA-A*0201-expressing
      allogeneic melanoma cell lines but was not reactive with normal melanocytes.
      Here, we report the full molecular characterization of the target structure for
      CTL 1/29, which was identified by cDNA expression cloning. The recognized antigen
      was named CAMEL (CTL-recognized antigen on melanoma). The CAMEL cDNA turned out
      to be derived from the LAGE-1 gene, a recently described tumor antigen that is
      strongly homologous to NY-ESO-1. CAMEL, however, is not encoded by the putative
      open reading frame (ORF) of LAGE-1 but by an alternative frame starting from the 
      second ATG of the mRNA. The first 11 amino acids of the CAMEL protein,
      MLMAQEALAFL, constitute the epitope of CTL 1/29. This epitope is also encoded by 
      a similar alternative ORF in NY-ESO-1. In summary, CTL induction with
      IL-2-transfected melanoma cells has revealed a new tumor antigen that may serve
      as a target for immunotherapy.
FAU - Aarnoudse, C A
AU  - Aarnoudse CA
AD  - Department of Clinical Oncology, Leiden University Medical Center, The
      Netherlands.
FAU - van den Doel, P B
AU  - van den Doel PB
FAU - Heemskerk, B
AU  - Heemskerk B
FAU - Schrier, P I
AU  - Schrier PI
LA  - eng
SI  - GENBANK/AJ012833
SI  - GENBANK/AJ012834
SI  - GENBANK/AJ012835
PT  - Journal Article
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (DNA, Complementary)
RN  - 0 (Interleukin-2)
SB  - IM
MH  - Amino Acid Sequence
MH  - Animals
MH  - Antibody Specificity
MH  - Antigens, Neoplasm/*genetics
MH  - Base Sequence
MH  - COS Cells
MH  - Cloning, Molecular
MH  - DNA, Complementary/genetics
MH  - Epitope Mapping
MH  - Genetic Code
MH  - Humans
MH  - Interleukin-2/*therapeutic use
MH  - Molecular Sequence Data
MH  - Protein Biosynthesis/*drug effects
MH  - Sequence Homology, Nucleic Acid
MH  - T-Lymphocytes, Cytotoxic/*drug effects/immunology
MH  - Tumor Cells, Cultured
EDAT- 1999/07/10 10:00
MHDA- 2000/06/20 09:00
CRDT- 1999/07/10 10:00
PHST- 1999/07/10 10:00 [pubmed]
PHST- 2000/06/20 09:00 [medline]
PHST- 1999/07/10 10:00 [entrez]
AID - 10.1002/(SICI)1097-0215(19990730)82:3<442::AID-IJC19>3.0.CO;2-Z [pii]
AID - 10.1002/(sici)1097-0215(19990730)82:3<442::aid-ijc19>3.0.co;2-z [doi]
PST - ppublish
SO  - Int J Cancer. 1999 Jul 30;82(3):442-8. doi:
      10.1002/(sici)1097-0215(19990730)82:3<442::aid-ijc19>3.0.co;2-z.